ICON is pleased to host an upcoming in person seminar focused on advancing Chinese biopharmaceutical innovation on the global stage. The event will take place on 14 May 2026, from 3:30pm to 6:00pm, at the Evergreen Laur...

Study start-up timelines continue to stretch, despite better tools and more process. In this Journal for Clinical Studies article, Brian Mallon argues the real blockers are human, not technical, from communication gaps t...

ICON Biotech is exhibiting and presenting at #OCTEU26, 6–7 May in Barcelona. Visit booth \#52 to engage with the ICON team and learn how our biotech-focused solutions help sponsors navigate clinical development throughou...

First in human development of oligonucleotide drugs requires careful safety evaluation as molecular complexity increases. In this webinar, ICON specialists discuss best practices for FIH ON study design and risk mitiga...

Join ICON Biotech at OCT East Coast 2026, taking place 12–13 May 2026 at the Hyatt Regency New Brunswick, New Jersey. Meet our team at Booth \#25 and explore how our specialised clinical development services can suppor...

If recruitment and retention matter, site satisfaction must be treated as a prerequisite. In this Journal for Clinical Studies article, Brian Mallon explains why start-up success is shaped by human factors, not technolog...

Ankita Minhas will speak on 6 May at OCT Europe in Barcelona at 12:00pm in Stream C. Her session will explore how leading biotechs manage rising complexity through AI-driven innovation, smarter trial designs, and stronge...

Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our free monthly publication b...

Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...

Oligonucleotide (ON) drug development is accelerating rapidly—but first in human (FIH) studies remain complex. Join our upcoming webinar to explore key translational and clinical considerations for initiating FIH antis...

Faster study start up starts with the right sites, and the right tools. Speak with us at ASCO, booth \#35093 to learn about ICON’s purpose built technology suite that helps sponsors identify, activate and collaborate wi...

Great discussion recently at European Pharmaceutical Review’s webinar, “Harnessing AI for more efficient clinical trials.” ICON’s SVP of Enterprise AI, Tony Clarke, joined a panel of industry leaders to share perspectiv...